Nasdaq

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

– Positive responses from surgeons and trauma centers to initial sales and marketing outreach – To communicate the health economic value of Symvess, Humacyte has developed a Budget Impact Model (BIM) ...
Nasdaq

Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Seeking Alpha

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

- After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - - Results represent first prospective long-term data in ...
Seeking Alpha

Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

DURHAM, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today ...